Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Sulfated Glucuronorhamnoxylan from Capsosiphon fulvescens Ameliorates Osteoporotic Bone Resorption via Inhibition of Osteoclastic Cell Differentiation and Function In Vitro and In Vivo

SC. Kim, HJ. Kim, GE. Park, CW. Lee, A. Synytsya, P. Capek, YI. Park

. 2022 ; 24 (4) : 690-705. [pub] 20220707

Language English Country United States

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 1999-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 1999-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1999-01-01 to 1 year ago

Excessive osteoclast differentiation and/or bone resorptive function causes a gradual loss of bone, leading to the pathogenesis of bone diseases such as osteoporosis (OP). In this study, a sulfated glucuronorhamnoxylan polysaccharide (designated SPS-CF) of the green alga Capsosiphon fulvescens was evaluated for anti-osteoporotic activity using osteoclastic cells differentiated from RAW264.7 macrophages by receptor activator of NF-κB ligand (RANKL) treatment and ovariectomized (OVX) female mice as a postmenopausal OP model. With negligible cytotoxicity, SPS-CF (50 μg/mL) significantly suppressed tartrate-resistant acid phosphatase (TRAP) activity, actin ring formation, and expression of matrix metalloproteinase 9 (MMP-9), cathepsin K, TRAF6, p-Pyk2, c-Cbl, c-Src, gelsolin, carbonic anhydrase II (CA II), and integrin β3, indicating that SPS-CF inhibits the differentiation and bone resorptive function of osteoclasts. Removal of sulfate groups from SPS-CF abolished its anti-osteoclastogenic activities, demonstrating that sulfate groups are critical for its activity. Oral administration of SPS-CF (400 mg/kg/day) to OVX mice significantly augmented the bone mineral density (BMD) and serum osteoprotegerin (OPG)/RANKL ratio. These results demonstrated that SPS-CF exerts significant anti-osteoporotic activity by dampening osteoclastogenesis and bone resorption via downregulation of TRAF6-c-Src-Pyk2-c-Cbl-gelsolin signaling and augmentation of serum OPG/RANKL ratios in OVX mice, suggesting that SPS-CF can be a novel anti-osteoporotic compound for treating postmenopausal OP.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025078
003      
CZ-PrNML
005      
20221031101146.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10126-022-10136-w $2 doi
035    __
$a (PubMed)35796894
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kim, Seong Cheol $u Department of Biotechnology, Graduate School, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea
245    10
$a Sulfated Glucuronorhamnoxylan from Capsosiphon fulvescens Ameliorates Osteoporotic Bone Resorption via Inhibition of Osteoclastic Cell Differentiation and Function In Vitro and In Vivo / $c SC. Kim, HJ. Kim, GE. Park, CW. Lee, A. Synytsya, P. Capek, YI. Park
520    9_
$a Excessive osteoclast differentiation and/or bone resorptive function causes a gradual loss of bone, leading to the pathogenesis of bone diseases such as osteoporosis (OP). In this study, a sulfated glucuronorhamnoxylan polysaccharide (designated SPS-CF) of the green alga Capsosiphon fulvescens was evaluated for anti-osteoporotic activity using osteoclastic cells differentiated from RAW264.7 macrophages by receptor activator of NF-κB ligand (RANKL) treatment and ovariectomized (OVX) female mice as a postmenopausal OP model. With negligible cytotoxicity, SPS-CF (50 μg/mL) significantly suppressed tartrate-resistant acid phosphatase (TRAP) activity, actin ring formation, and expression of matrix metalloproteinase 9 (MMP-9), cathepsin K, TRAF6, p-Pyk2, c-Cbl, c-Src, gelsolin, carbonic anhydrase II (CA II), and integrin β3, indicating that SPS-CF inhibits the differentiation and bone resorptive function of osteoclasts. Removal of sulfate groups from SPS-CF abolished its anti-osteoclastogenic activities, demonstrating that sulfate groups are critical for its activity. Oral administration of SPS-CF (400 mg/kg/day) to OVX mice significantly augmented the bone mineral density (BMD) and serum osteoprotegerin (OPG)/RANKL ratio. These results demonstrated that SPS-CF exerts significant anti-osteoporotic activity by dampening osteoclastogenesis and bone resorption via downregulation of TRAF6-c-Src-Pyk2-c-Cbl-gelsolin signaling and augmentation of serum OPG/RANKL ratios in OVX mice, suggesting that SPS-CF can be a novel anti-osteoporotic compound for treating postmenopausal OP.
650    _2
$a zvířata $7 D000818
650    12
$a resorpce kosti $x farmakoterapie $7 D001862
650    _2
$a buněčná diferenciace $7 D002454
650    12
$a Chlorophyta $x metabolismus $7 D000460
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fokální adhezní kinasa 2 $x metabolismus $7 D051418
650    _2
$a gelsolin $x metabolismus $7 D018260
650    _2
$a myši $7 D051379
650    _2
$a NF-kappa B $x metabolismus $7 D016328
650    12
$a osteoporóza $x farmakoterapie $7 D010024
650    _2
$a sírany $x metabolismus $7 D013431
650    _2
$a faktor 6 asociovaný s receptory TNF $x metabolismus $7 D048029
650    _2
$a kyselá fosfatasa rezistentní k tartarátu $x metabolismus $7 D000071681
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kim, Hyeon Jeong $u Department of Biotechnology, Graduate School, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea
700    1_
$a Park, Gi Eun $u Department of Biotechnology, Graduate School, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea
700    1_
$a Lee, Chang Won $u Department of Biotechnology, Graduate School, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea
700    1_
$a Synytsya, Andriy $u Department of Carbohydrate Chemistry and Technology, University of Chemistry and Technology in Prague, Technická 5, 166 28, Prague, 6, Czech Republic
700    1_
$a Capek, Peter $u Institute of Chemistry, Centre for Glycomics, Slovak Academy of Sciences, Dúbravská cesta 9, 845 38, Bratislava, Slovakia
700    1_
$a Park, Yong Il $u Department of Biotechnology, Graduate School, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea. yongil382@catholic.ac.kr $u Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea. yongil382@catholic.ac.kr $1 https://orcid.org/http://orcid.org/0000000217490689
773    0_
$w MED00005772 $t Marine biotechnology $x 1436-2236 $g Roč. 24, č. 4 (2022), s. 690-705
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35796894 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101143 $b ABA008
999    __
$a ok $b bmc $g 1854673 $s 1176368
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 24 $c 4 $d 690-705 $e 20220707 $i 1436-2236 $m Marine biotechnology $n Mar Biotechnol (NY) $x MED00005772
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...